← Hims Hers Health overview

Hims Hers Health vs CVS Health: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Hims Hers Health Inc (HIMS)

Q3 2026
▲2▼2

Hims & Hers grew fast but faced FTC suit and cash burn

  • Strong revenue and subscriber growth Revenue jumped 38% to $753.2M and subscribers rose 18.5% to about 2.9 million, prompting management to raise full-year guidance to $3.1–3.3 billion. This shows the core business is still expanding quickly.

    It explains the main positive force behind the quarter's results.

  • GLP-1 momentum and international expansion Barclays raised its price target to $39, citing momentum in weight-loss drugs (GLP-1s), helped by the Novo Nordisk partnership and the Eucalyptus acquisition that expands into the UK, Australia, and Canada.

    It highlights a key growth driver and analyst optimism that supported the stock.

  • FTC lawsuit and legal probes An FTC lawsuit over health-data sharing and deceptive billing sank the stock 14.7% and triggered multiple law-firm investigations. This regulatory risk weighed heavily on investor sentiment.

    It was the biggest negative event that hurt the stock during the quarter.

  • Financial deterioration and operational issues Q2 swung to a $0.37 loss, gross margin fell to about 64%, free cash flow turned negative $68M, and Visa placed HIMS in a chargeback-monitoring program. Leadership departures and a 51% yearly stock drop fueled takeover talk.

    It shows the financial and operational setbacks that pressured the stock.

August 2026
▼2▲1

Hims & Hers: strong sales but losses, legal and payment risks hit stock

  • Revenue and subscriber growth beat expectations Revenue rose 38% to $753.2M, beating estimates, and full-year guidance was raised to $3.1–$3.3B. Subscribers grew 18.5% to about 2.9 million, showing demand for its health and weight-loss services remains strong.

    This is the main positive force behind the stock, showing the business is still growing quickly.

  • Profit turned to loss as costs and margins worsened Q2 swung to a $0.37 loss from a $0.17 profit, gross margin fell to about 64% from 76%, free cash flow turned negative $68M, and operating expenses jumped 48.4%. This shows growth is coming at a high cost.

    This explains why the stock fell despite strong revenue, as profitability and cash flow deteriorated.

  • Visa dispute program and lawsuits raise risk Visa placed HIMS in a dispute-monitoring program over weight-loss subscription chargebacks, while FTC, state, and class-action lawsuits over billing and privacy raise costs and reputational risk. These issues threaten its payment processing and trust with customers.

    This is a new negative development that adds to legal and operational uncertainty, weighing on the stock.

  • Leadership change and takeover talk amid weak stock The chief accounting officer is departing, and the stock fell 51% in a year, prompting takeover speculation despite CEO voting control and about $1B convertible debt. JPMorgan initiated at Neutral with a $32 target, citing execution risk in branded GLP-1s.

    This captures the mixed sentiment: management turnover and a weak stock invite takeover talk, but analysts see execution risk.

Latest
▼2

HIMS: legal risk, leadership exit, and a 51% slump reshape the story

  • Privacy investigations and class action raise legal risk Law firms are investigating and suing Hims & Hers over claims it shared users' private health data and mishandled billing. Legal fights like this can bring fines, payouts, and bad publicity, which weighs on the stock because investors worry about cost and reputation.

    New legal and regulatory threats are a fresh, material drag on HIMS.

  • Chief accounting officer to leave in October Hims & Hers said its chief accounting officer, Irene Becklund, will depart on October 9, 2026, after seven years. The CFO will cover the role while a replacement is found. A key finance leader leaving adds uncertainty, which can pressure the stock.

    A senior finance departure is a new event that creates uncertainty for investors.

  • Stock down 51% makes HIMS a takeover candidate After a 51% one-year drop, Hims & Hers is being talked about as a possible acquisition target for Amazon, UnitedHealth, CVS, or Pfizer, though its CEO controls voting shares and about $1 billion in convertible debt complicates any deal. Takeover talk can support the stock, but the weak price and debt are negatives.

    The steep decline and buyout speculation are new and directly shape how investors value HIMS.

  • JPMorgan starts coverage at Neutral with $32 target JPMorgan began covering Hims & Hers with a Neutral rating and a $32 price target, saying growth is strong but the shift to branded weight-loss drugs like Wegovy carries execution risk. A neutral start with a target near the current price gives little fresh upside push.

    A major bank's first rating is a new signal that frames the bull and bear case.

▼3▲1

Visa billing crackdown and FTC lawsuit hit HIMS; growth stays strong

  • Visa puts HIMS in dispute-monitoring program Visa placed Hims & Hers in its Acquirer Monitoring Program after a surge in credit-card disputes tied to weight-loss subscriptions, with a possible $75,000 penalty and a requirement to keep disputes below 1.5% for three months. This threatens billing reliability and could slow subscriber growth, pushing the stock down.

    This is the main new negative event this period and directly pressures HIMS's price.

  • FTC and state regulators escalate legal action The FTC and state regulators filed a civil enforcement action, and a consumer class action targets privacy and subscription practices. The CEO says the FTC misunderstands the company, but the legal fight adds costs and reputational risk that weigh on the stock.

    This is a new escalation of the legal pressure that is a core driver of HIMS's risk profile.

  • Q2 revenue jumps 38% and outlook raised Hims & Hers raised its 2026 revenue outlook to $3.1–$3.3 billion after Q2 sales rose 38.2% to $753.2 million, beating estimates. Subscribers grew 18.5% to about 2.9 million, showing demand is still strong and supporting the stock.

    This is the main new positive fundamental update this period and shows the growth story remains intact.

  • Margins shrink and cash burn deepens Gross margin fell to 63.8% from 76%, operating expenses rose 48.4%, and free cash flow was negative $68 million with an $86.3 million net loss. The company is spending heavily to grow, which pressures profits and keeps the stock volatile.

    This is the key counterweight to the revenue beat and explains why the stock still faces pressure.

▼2

HIMS Q2 loss and margin hit overshadow revenue beat

  • Q2 loss and margin collapse Hims & Hers reported a second-quarter loss of $0.37 per share, swinging from a $0.17 profit a year earlier. Gross margin fell to 64% from 76%, hit by an $81 million one-time cost tied to the Eucalyptus acquisition, a weight-loss strategy shift, and FTC legal reserves. This profit miss is what pushed the stock down.

    The earnings miss and margin drop are the main new financial event driving the stock lower this period.

  • Revenue beat and raised guidance Revenue rose 38% to $753.2 million, beating the roughly $699 million analysts expected, and the company raised its full-year revenue outlook to $3.1 billion to $3.3 billion. This shows demand is still strong, but investors focused on the loss and costs, so the stock still fell.

    It is the positive counterweight in the same earnings report and explains why the selloff was not larger.

  • CEO defends FTC lawsuit, touts cheaper GLP-1s CEO Andrew Dudum said the FTC lawsuit is more about publicity than a real resolution, and he expects cash-paying patients to eventually pay $40 to $50 a month for branded weight-loss drugs, down from $150 to $200. Cheaper pricing could boost demand, but the lawsuit still threatens fines and trust.

    It updates the biggest legal overhang and gives a concrete path to lower prices that could help future demand.

  • Weight-loss pill market cost pressure Hims & Hers and Novo Nordisk both fell even after strong growth, as investors worried about rising costs in the weight-loss pill market. Novo Nordisk's Wegovy pill sales missed expectations, adding to concerns that the branded GLP-1 push may be less profitable than hoped.

    It shows the cost and competition pressure in the core weight-loss business that is weighing on HIMS shares.

July 2026
▲2▼2

HIMS: FTC privacy lawsuit and law firm probes hit growth story

  • GLP-1 inflection and FDA peptide decision Barclays raised its price target to $39, citing a clear pickup in Hims & Hers' GLP-1 weight-loss business after the Novo Nordisk partnership, with website traffic up 35% and app users up 21%. A July FDA committee decision on peptides could open another growth avenue.

    This is the main positive force behind the stock and explains why it had been rising before the FTC news.

  • Novo Nordisk deal and Eucalyptus acquisition expand reach Hims & Hers is deepening its move into prescription weight management by offering Novo Nordisk's Wegovy and Ozempic, and its Eucalyptus acquisition adds scale in the UK, Australia, and Canada. This broadens revenue sources but raises questions about margins and regulatory exposure.

    It shows the concrete business expansion driving the growth narrative, a key reason investors were optimistic.

  • FTC lawsuit over data sharing and billing The FTC sued Hims & Hers, alleging it shared users' health data with advertisers like Meta and Snap and used deceptive billing and cancellation practices. The stock fell about 14.7% on the news, as the lawsuit threatens fines, reputational damage, and its core trust-based business model.

    This is the biggest new negative event and the main reason the stock dropped sharply this period.

  • Multiple law firm investigations into securities law violations Several law firms, including Holzer & Holzer, Frank R. Cruz, Kessler Topaz, and Lowey Dannenberg, are investigating whether Hims & Hers misled investors about the FTC allegations. These probes can lead to class-action lawsuits, adding legal costs and uncertainty that weigh on the stock.

    It shows the FTC issue is escalating into potential investor lawsuits, a fresh negative overhang.

▲2▼2

HIMS: FTC privacy lawsuit and law firm probes hit growth story

  • GLP-1 inflection and FDA peptide decision Barclays raised its price target to $39, citing a clear pickup in Hims & Hers' GLP-1 weight-loss business after the Novo Nordisk partnership, with website traffic up 35% and app users up 21%. A July FDA committee decision on peptides could open another growth avenue.

    This is the main positive force behind the stock and explains why it had been rising before the FTC news.

  • Novo Nordisk deal and Eucalyptus acquisition expand reach Hims & Hers is deepening its move into prescription weight management by offering Novo Nordisk's Wegovy and Ozempic, and its Eucalyptus acquisition adds scale in the UK, Australia, and Canada. This broadens revenue sources but raises questions about margins and regulatory exposure.

    It shows the concrete business expansion driving the growth narrative, a key reason investors were optimistic.

  • FTC lawsuit over data sharing and billing The FTC sued Hims & Hers, alleging it shared users' health data with advertisers like Meta and Snap and used deceptive billing and cancellation practices. The stock fell about 14.7% on the news, as the lawsuit threatens fines, reputational damage, and its core trust-based business model.

    This is the biggest new negative event and the main reason the stock dropped sharply this period.

  • Multiple law firm investigations into securities law violations Several law firms, including Holzer & Holzer, Frank R. Cruz, Kessler Topaz, and Lowey Dannenberg, are investigating whether Hims & Hers misled investors about the FTC allegations. These probes can lead to class-action lawsuits, adding legal costs and uncertainty that weigh on the stock.

    It shows the FTC issue is escalating into potential investor lawsuits, a fresh negative overhang.

CVS Health Corp (CVS)

Q3 2026
▲2▼2

CVS beats Q2, raises guidance, but 2027 caution and regulatory threats weigh

  • Q2 earnings beat and raised 2026 guidance CVS beat Q2 estimates and raised 2026 guidance across pharmacy and Aetna, with $3–$4 of embedded EPS from the Aetna turnaround and $2 billion in Medicare Advantage bonuses. This strong performance supports the stock.

    It shows the company's current financial strength and improved outlook, a key positive driver.

  • FTC settlement and new partnerships An FTC settlement removed legal uncertainty, Health Services revenue rose 11.5%, and new partnerships with Eli Lilly, McKesson, and Cardinal Health strengthen weight management and drug supply. Walgreens closures may shift suburban customers to CVS.

    These developments reduce risk and open growth opportunities, supporting the stock.

  • Cautious 2027 guidance and competitive pressures Shares fell 8% on cautious 2027 guidance citing Caremark membership declines, 340B headwinds, and GLP-1 competition from Walmart and Amazon. These factors threaten future growth and pressured the stock.

    It explains the main negative price driver during the period.

  • Regulatory and cost headwinds Senator Warren's bipartisan breakup bill threatens CVS's vertical integration, while elevated medical costs, Medicare Advantage pullbacks, and Inflation Reduction Act drug price cuts continue pressuring profits and capping upside despite a cheap valuation.

    These ongoing risks limit the stock's potential and weigh on investor sentiment.

August 2026
▲2▼2

CVS raises guidance on Aetna turnaround, but breakup bill and headwinds cap gains

  • Aetna turnaround drives guidance raises CVS raised its 2026 profit and revenue outlook twice, with Aetna's operating profit forecast up over $1 billion. Q2 earnings jumped 42.5%, showing the insurance unit's recovery is gaining traction.

    This is the main positive force behind CVS's improved financial outlook and stock support during the period.

  • New partnerships expand weight management and secure drug supply CVS partnered with Eli Lilly to expand its weight management program and extended supply deals with McKesson and Cardinal Health. These moves strengthen its competitive position in a growing market and ensure long-term drug availability.

    These strategic deals are new developments that support future growth and operational stability.

  • Senator Warren's breakup bill threatens vertical integration A bipartisan bill from Senator Warren aims to break up CVS's combined insurance, pharmacy, and benefit manager operations. If passed, it could fundamentally reshape the company and limit its ability to control costs and care.

    This regulatory risk is a major new overhang that could significantly alter CVS's business model and cap stock gains.

  • Persistent headwinds limit upside despite cheap valuation 340B pricing pressure, declining pharmacy benefit membership, Medicare Advantage pullbacks for 2027, and reimbursement pressure continue to threaten future profits. These unresolved issues keep the stock inexpensive and cap potential gains.

    These ongoing challenges are a key counterweight to the positive momentum and explain why the stock remains undervalued.

Latest
▲3▼1

CVS Raises 2026 Guidance Again as Aetna Improves and Supply Deals Lock In

  • CVS lifts 2026 revenue and earnings guidance CVS raised its 2026 revenue outlook to at least $414 billion and adjusted earnings to $7.90-$8.10 per share, up from $7.30-$7.50. Higher profit expectations make the stock more attractive to investors, pushing the price up.

    This is the core new event showing the company's financial outlook improving, directly lifting the stock.

  • Aetna health benefits profit outlook jumps by over $1 billion CVS now expects its Aetna insurance unit to earn $5.03-$5.37 billion in operating profit for the year, more than $1 billion above prior guidance, after a strong first half. This signals the insurance turnaround is working, supporting a higher stock price.

    This is a fresh, specific upgrade to the most troubled part of CVS, directly boosting investor confidence.

  • Long-term drug supply secured with McKesson and Cardinal Health McKesson agreed to extend its drug distribution deal with CVS through June 2032, and Cardinal Health signed a letter of intent for a similar extension. Locking in supply reduces disruption risk and supports steady pharmacy operations, a mild positive for the stock.

    New agreements reduce a key operational risk and reassure investors about CVS's supply chain.

  • Medicare Advantage pullback and cost pressures persist CVS's Aetna unit is among insurers cutting Medicare Advantage offerings for 2027 amid rising medical costs and government scrutiny. Fewer plan choices may slow membership growth, and reimbursement pressure remains a drag on future profits.

    This is the main counterweight: it shows a real headwind that could limit how much the stock can rise.

September 2026
▲3▼1

CVS Raises Guidance Across All Units, But Cost and Regulatory Pressures Persist

  • CVS raises 2026 profit guidance for pharmacy and Aetna units CVS lifted full-year profit guidance for its pharmacy segment to at least $6.4 billion and its Aetna insurance unit to $5.03–$5.37 billion, both well above prior targets. This shows the company's turnaround is working, which supports the stock price.

    This is the core new positive event of the period, directly raising profit expectations and boosting investor confidence.

  • Walgreens closures hand CVS suburban pharmacy customers Walgreens is closing about 1,200 stores through 2027, pushing suburban customers to CVS without any marketing effort. CVS is also opening small-format stores and adding GLP-1 access, which should lift pharmacy sales and market share.

    This is a new competitive development that directly benefits CVS's pharmacy business and is not in earlier reports.

  • Health Services revenue jumps 11.5% with strong selling season CVS's Health Services segment posted $51.8 billion in Q2 revenue, up 11.5%, and adjusted operating income rose 10% to $1.73 billion. The 2026 selling season brought over $6 billion in new sales, well above historical averages, signaling future growth.

    This new segment-level detail shows broad-based strength beyond the headline earnings beat, supporting the bull case.

  • Elevated medical costs and regulatory pricing pressure linger CVS said at a conference it still faces elevated medical costs, which dragged managed care stocks. Separately, regulatory drug price cuts under the Inflation Reduction Act continue to pressure pharmacy revenues, though profit impact is limited so far.

    This is the main counterweight to the positive guidance news, reminding investors that cost and regulatory headwinds remain unresolved.

▲3▼1

CVS Raises Guidance Across All Units, But Cost and Regulatory Pressures Persist

  • CVS raises 2026 profit guidance for pharmacy and Aetna units CVS lifted full-year profit guidance for its pharmacy segment to at least $6.4 billion and its Aetna insurance unit to $5.03–$5.37 billion, both well above prior targets. This shows the company's turnaround is working, which supports the stock price.

    This is the core new positive event of the period, directly raising profit expectations and boosting investor confidence.

  • Walgreens closures hand CVS suburban pharmacy customers Walgreens is closing about 1,200 stores through 2027, pushing suburban customers to CVS without any marketing effort. CVS is also opening small-format stores and adding GLP-1 access, which should lift pharmacy sales and market share.

    This is a new competitive development that directly benefits CVS's pharmacy business and is not in earlier reports.

  • Health Services revenue jumps 11.5% with strong selling season CVS's Health Services segment posted $51.8 billion in Q2 revenue, up 11.5%, and adjusted operating income rose 10% to $1.73 billion. The 2026 selling season brought over $6 billion in new sales, well above historical averages, signaling future growth.

    This new segment-level detail shows broad-based strength beyond the headline earnings beat, supporting the bull case.

  • Elevated medical costs and regulatory pricing pressure linger CVS said at a conference it still faces elevated medical costs, which dragged managed care stocks. Separately, regulatory drug price cuts under the Inflation Reduction Act continue to pressure pharmacy revenues, though profit impact is limited so far.

    This is the main counterweight to the positive guidance news, reminding investors that cost and regulatory headwinds remain unresolved.

▲2▼1

CVS's Aetna Turnaround Delivers, But Breakup Bill and 2027 Headwinds Loom

  • Aetna's lower medical costs drive earnings beat and raised guidance CVS's Aetna insurance unit benefited from lower medical costs in Q2, helping CVS beat earnings estimates and raise its 2026 adjusted EPS guidance to $7.90–$8.10. This shows the turnaround is working, which supports the stock price.

    This is the core positive driver this period, showing real profit improvement that directly lifts investor confidence.

  • Senator Warren pushes bill to break up CVS's vertical integration Senator Elizabeth Warren is pushing a bipartisan bill that would force CVS to split its insurance and pharmacy businesses. If passed, this would fundamentally change how CVS operates and could hurt profits, creating uncertainty that weighs on the stock.

    This is a new regulatory threat with potential to reshape the company, directly answering why CVS faces downward pressure.

  • CVS revamps weight management program with Eli Lilly partnership CVS expanded its weight management program, partnering with Eli Lilly to offer Zepbound through its app and lowering MinuteClinic visits to $29. This aims to capture growing demand for GLP-1 drugs, which could boost pharmacy traffic and sales.

    This is a new strategic move to capture a high-growth market, showing how CVS is positioning for future demand.

  • Strong earnings momentum but 2027 headwinds remain CVS's Q2 earnings rose 42.5% and cash flow is strong, but management warned of 340B drug pricing pressure and lower pharmacy benefit membership in 2027. The stock trades cheaply, but these unresolved risks keep a lid on gains.

    This captures the balance of positive momentum against real future challenges, giving a fair picture of what's driving the stock.

July 2026
▲3▼1

CVS beats Q2, raises guidance, but cautious 2027 outlook sinks shares

  • Aetna turnaround and Medicare Advantage bonuses CVS quantified $3–$4 of embedded earnings per share from its Aetna turnaround and expects $2 billion in 2026 Medicare Advantage quality bonuses, signaling improved profitability in its insurance unit.

    This shows a key profit driver that boosted investor confidence during the period.

  • FTC settlement removes legal uncertainty CVS reached a settlement with the FTC, removing a major legal cloud that had been hanging over the company and allowing management to focus on operations.

    This was a new positive development that reduced regulatory risk for CVS.

  • Q2 earnings beat and raised guidance CVS reported Q2 adjusted EPS of $2.58 and revenue over $106 billion, beating estimates, and raised its 2026 guidance while setting a preliminary 2027 EPS floor of $8.44, about 13% growth.

    This is the core financial update that drove the stock's initial positive reaction.

  • Cautious 2027 outlook and persistent headwinds Despite the Q2 beat, CVS gave cautious 2027 guidance, citing expected Caremark membership declines, continued 340B headwinds, and intense GLP-1 competition from Walmart and Amazon. Shares fell 8% on the outlook.

    This explains the main negative force that pulled the stock down during the period.

▲3▼1

CVS beats and raises guidance, but cautious 2027 outlook and GLP-1 competition weigh

  • Q2 beat and raised 2026 guidance CVS reported Q2 adjusted EPS of $2.58 on revenue over $106 billion, beating estimates, and raised 2026 adjusted EPS guidance to $7.90–$8.10. Adjusted operating income jumped 35% to about $5.2 billion, showing the Aetna turnaround is delivering real profit growth.

    This is the core new financial result that directly moves the stock and confirms the recovery story.

  • 2027 EPS floor and 13% growth target Management set a preliminary 2027 adjusted EPS floor of $8.44, about 13% growth from 2026, and forecast at least $11.5 billion in operating cash flow. This gives investors a concrete multi-year earnings path, supporting the stock despite near-term caution.

    It provides forward visibility that investors use to value the stock and judge the durability of the turnaround.

  • GLP-1 push with $29 MinuteClinic visits and Lilly deal CVS revamped its weight management program with $29 virtual visits and a Lilly collaboration for transparent Zepbound pricing, aiming to capture GLP-1 prescriptions as employers drop coverage. This could boost pharmacy traffic and customer loyalty, though competition from Walmart and Amazon is intense.

    It is a new growth initiative that could drive demand and offset other pressures, directly affecting future revenue.

  • Cautious guidance and 2027 headwinds Despite the beat, CVS gave cautious guidance, sending shares down 8% on the day. Management flagged expected membership declines in Caremark and continued 340B headwinds for 2027, which could pressure future profits and temper the upbeat long-term targets.

    It is the main counterweight that explains why the stock fell even after strong results and raised guidance.

▲3▼1

CVS Gains on Aetna Turnaround, Medicare Bonus, and FTC Settlement

  • Aetna turnaround quantified Management quantified $3–$4 of embedded EPS from Aetna's margin recovery, raised 2025 guidance, and trimmed unprofitable Medicare Advantage and ACA plans. This gives investors a concrete path to higher profits, pushing the stock up.

    It explains the core profit-recovery story driving the stock's 57% surge.

  • Medicare Advantage bonus payments CVS is expected to receive $2 billion in federal quality bonus payments for 2026, as more plans earn four stars or higher. This is direct extra revenue for its insurance unit, supporting earnings and the stock price.

    It is a new, material cash inflow that boosts CVS's Medicare Advantage profitability.

  • FTC settlement removes legal overhang CVS Caremark settled the FTC's rebate lawsuit, agreeing to pricing reforms like capping insulin at $25 and increasing transparency. This removes a major legal uncertainty, which investors see as reducing risk and lifting the stock.

    It resolves a key regulatory threat that had been weighing on the shares.

  • Legal and regulatory headwinds persist CVS agreed to pay $440 million to settle a false billing case, and Henry Ford Health sued over $29 million in 340B drug discounts. These add costs and uncertainty, but are smaller than the positive drivers and may not derail the recovery.

    It provides a fair counterweight, showing that legal risks remain even as the core business improves.

Q2 2026
▲2▼2

CVS expands GLP-1 access but faces antitrust and Medicare scrutiny

  • GLP-1 access program CVS launched a GLP-1 support program across 9,000 pharmacies, offering $49 virtual visits and medications as low as $25/month. This could boost retail pharmacy revenue and patient demand, pushing the stock up.

    This is a new initiative that directly drives future revenue and demand for CVS's pharmacy and clinic services.

  • Florida antitrust probe Florida's Attorney General opened an antitrust investigation into CVS's pharmacy and PBM operations, demanding documents by July 28. This regulatory risk could lead to fines or business changes, weighing on the stock.

    This is a new regulatory threat that could result in penalties or operational restrictions, directly impacting CVS's valuation.

  • Medicare Advantage denial scrutiny A New York Times report highlighted high denial rates for rehab care by CVS and other Medicare Advantage insurers. This scrutiny could lead to stricter regulations or reputational damage, pressuring the stock.

    This new negative media coverage raises regulatory and reputational risks that could affect CVS's Medicare Advantage business.

  • Strong Q1 earnings beat CVS reported Q1 revenue of $100.4 billion, beating estimates by 6.3% and up 6.2% year-over-year. This strong financial performance supports the stock price and investor confidence.

    This is a new earnings result that demonstrates CVS's financial health and outperformance versus peers.

June 2026
▲2▼2

CVS expands GLP-1 access but faces antitrust and Medicare scrutiny

  • GLP-1 access program CVS launched a GLP-1 support program across 9,000 pharmacies, offering $49 virtual visits and medications as low as $25/month. This could boost retail pharmacy revenue and patient demand, pushing the stock up.

    This is a new initiative that directly drives future revenue and demand for CVS's pharmacy and clinic services.

  • Florida antitrust probe Florida's Attorney General opened an antitrust investigation into CVS's pharmacy and PBM operations, demanding documents by July 28. This regulatory risk could lead to fines or business changes, weighing on the stock.

    This is a new regulatory threat that could result in penalties or operational restrictions, directly impacting CVS's valuation.

  • Medicare Advantage denial scrutiny A New York Times report highlighted high denial rates for rehab care by CVS and other Medicare Advantage insurers. This scrutiny could lead to stricter regulations or reputational damage, pressuring the stock.

    This new negative media coverage raises regulatory and reputational risks that could affect CVS's Medicare Advantage business.

  • Strong Q1 earnings beat CVS reported Q1 revenue of $100.4 billion, beating estimates by 6.3% and up 6.2% year-over-year. This strong financial performance supports the stock price and investor confidence.

    This is a new earnings result that demonstrates CVS's financial health and outperformance versus peers.

▲2▼2

CVS expands GLP-1 access but faces antitrust and Medicare scrutiny

  • GLP-1 access program CVS launched a GLP-1 support program across 9,000 pharmacies, offering $49 virtual visits and medications as low as $25/month. This could boost retail pharmacy revenue and patient demand, pushing the stock up.

    This is a new initiative that directly drives future revenue and demand for CVS's pharmacy and clinic services.

  • Florida antitrust probe Florida's Attorney General opened an antitrust investigation into CVS's pharmacy and PBM operations, demanding documents by July 28. This regulatory risk could lead to fines or business changes, weighing on the stock.

    This is a new regulatory threat that could result in penalties or operational restrictions, directly impacting CVS's valuation.

  • Medicare Advantage denial scrutiny A New York Times report highlighted high denial rates for rehab care by CVS and other Medicare Advantage insurers. This scrutiny could lead to stricter regulations or reputational damage, pressuring the stock.

    This new negative media coverage raises regulatory and reputational risks that could affect CVS's Medicare Advantage business.

  • Strong Q1 earnings beat CVS reported Q1 revenue of $100.4 billion, beating estimates by 6.3% and up 6.2% year-over-year. This strong financial performance supports the stock price and investor confidence.

    This is a new earnings result that demonstrates CVS's financial health and outperformance versus peers.